Physician profile
Ronny A Cohen
NPI 1205868874
$4,858.99
in general payments reported to CMS, 2019-2025
18 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,128 · 2020: $250 · 2021: $44.19 · 2022: $482 · 2023: $841 · 2024: $669 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,866 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.28 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,566.72 | 2019 | |
| Boston Scientific Corporation | $890.05 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Accolade Sr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.21 | 2022-2025 | Jardiance |
| Irhythm Technologies, INC. | $324.86 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Astrazeneca Pharmaceuticals LP | $250.42 | 2023-2024 | Andexxa, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $237.16 | 2022-2025 | Lifevest |
| Insmed, INC. | $230.67 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $214.00 | 2023 | Opsumit, Uptravi |
| Abbott Laboratories | $152.26 | 2024 | Mitraclip |
| Glaxosmithkline, LLC. | $120.45 | 2019 | |
| Novartis Pharmaceuticals Corporation | $102.12 | 2019 | |
| Neurocrine Biosciences, INC. | $89.97 | 2022-2025 | |
| Astellas Pharma US INC | $55.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $43.71 | 2020-2022 | |
| Amgen INC. | $24.82 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $21.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.96 | 2025 | Camzyos |
| Chiesi USA, INC. | $19.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronny Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.